Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose (lactulose) for Oral Solution, a prescription laxative, Vaprisol (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak for the treatment of H. pylori and duodenal ulcer disease, and Ethyol (amifostine) for Injection, for the treatment of oncology patients. The Company also owns rights to ifetroban and are developing Hepatoren (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, VasculanTM (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban, for the treatment of portal hypertension.

Show more
Type
Public
HQ
Nashville, US
Founded
1999
Size (employees)
82 (est)
Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, US
Report incorrect company information

Cumberland Pharmaceuticals Office Locations

Cumberland Pharmaceuticals has an office in Nashville
Nashville, US (HQ)
950 2525 West End Ave
Show all (1)
Report incorrect company information

Cumberland Pharmaceuticals Financials and Metrics

Cumberland Pharmaceuticals Financials

Cumberland Pharmaceuticals's revenue was reported to be $41.15 m in FY, 2017
USD

Revenue (Q1, 2018)

8.6 m

Gross profit (Q1, 2018)

7.1 m

Gross profit margin (Q1, 2018), %

82.2%

Net income (Q1, 2018)

(2.4 m)

EBIT (Q1, 2018)

(2.5 m)

Market capitalization (14-Jun-2018)

94.3 m

Closing share price (14-Jun-2018)

6

Cash (31-Mar-2018)

35.3 m
Cumberland Pharmaceuticals's current market capitalization is $94.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

32 m36.9 m33.5 m33 m41.2 m

Revenue growth, %

15%(9%)(1%)

Cost of goods sold

5.4 m5.1 m5 m6 m7.4 m

Gross profit

26.6 m31.8 m28.6 m27.1 m33.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

6.5 m8.1 m9.8 m9.7 m8.7 m8.9 m7.9 m7.7 m7.4 m8.8 m9.6 m8.7 m8.6 m

Cost of goods sold

1 m1.1 m1.3 m1.3 m1.2 m1.2 m980.2 k1.2 m1.2 m2 m1.4 m1.7 m1.5 m

Gross profit

5.5 m7 m8.5 m8.4 m7.5 m7.7 m6.9 m6.5 m6.3 m6.8 m8.3 m7 m7.1 m

Gross profit Margin, %

84%87%87%86%87%86%88%84%84%78%86%81%82%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

40.9 m39.9 m38.2 m34.5 m45.4 m

Accounts Receivable

Inventories

5.7 m5.6 m4.3 m5.4 m6.7 m

Current Assets

68.7 m70.8 m67.1 m65.5 m68.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

46 m39 m39.1 m39.6 m39 m38.9 m38.3 m36.4 m35.8 m35.5 m35 m34.6 m35.3 m

Inventories

5.4 m7.4 m7 m6.1 m4.6 m4.8 m4.2 m4.1 m4.9 m5 m5.6 m5.6 m6.7 m

Current Assets

78.3 m69.3 m70.6 m70.1 m67.5 m68.2 m67.7 m64.9 m64 m67 m63.5 m63.3 m66.8 m

PP&E

975 k809.2 k726.9 k731.1 k685.2 k568.8 k541.8 k558.2 k505.7 k482.6 k538.4 k495.3 k566.9 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(2.2 m)2.4 m671.1 k(1 m)(8 m)

Depreciation and Amortization

1.3 m2 m2.2 m2.4 m2.6 m

Inventories

495.5 k1.5 m1.3 m(1.1 m)(1.4 m)

Accounts Payable

1.5 m191.9 k2.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(832.5 k)275.2 k709.5 k729.2 k26.5 k394.3 k121.7 k(268.6 k)(60.9 k)95.5 k(1.3 m)(2.4 m)

Depreciation and Amortization

693 k

Inventories

7 m6.1 m4.6 m4.8 m4.2 m4.1 m4.9 m5 m(76.3 k)

Accounts Payable

4.2 m3.2 m3.4 m4.1 m4.1 m4.1 m3.7 m6.7 m7.3 m(1.3 m)
USDY, 2018

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information

Cumberland Pharmaceuticals News and Updates

Report incorrect company information